The Legal Battle Behind the Weight Loss Drug Ozempic lawsuit cases center on allegations that Novo Nordisk, the manufacturer of Ozempic (semaglutide), failed to adequately warn patients and prescribing physicians about the drug's potential to cause severe gastrointestinal conditions, most notably a condition called gastroparesis, sometimes described in plaintiff filings as "stomach paralysis." Gastroparesis is a condition in which the stomach cannot empty itself properly
These products are not drugs, foods, or cosmetics, and are not intended to diagnose, treat, cure, or prevent any disease
Pack reconstituted peptides in checked luggage with ice packs in an insulated container
Supported by: This work was funded by the Instituto de Salud Carlos III (ISCIII) to A.N
Ozempic solo est indicado y testado para el tratamiento de la diabetes tipo 2, mientras que Wegovy se ha desarrollado especficamente para el tratamiento del sobrepeso y la obesidad
These symptoms may sometimes represent hypoglycaemia, particularly when Ozempic is combined with insulin or sulfonylureas